Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Other Non-Current Liabilities (2016 - 2025)

Altimmune (ALT) has disclosed Other Non-Current Liabilities for 16 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 7.94% to $5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.8 million through Dec 2025, up 7.94% year-over-year, with the annual reading at $5.8 million for FY2025, 7.94% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $5.8 million at Altimmune, down from $5.8 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $7.0 million in Q3 2021, with the low at $16000.0 in Q1 2025.
  • Average Other Non-Current Liabilities over 5 years is $3.4 million, with a median of $5.3 million recorded in 2021.
  • The sharpest move saw Other Non-Current Liabilities tumbled 99.01% in 2022, then skyrocketed 22188.46% in 2025.
  • Over 5 years, Other Non-Current Liabilities stood at $6.1 million in 2021, then crashed by 99.01% to $60000.0 in 2022, then plummeted by 33.33% to $40000.0 in 2023, then surged by 13225.0% to $5.3 million in 2024, then increased by 7.94% to $5.8 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $5.8 million, $5.8 million, and $5.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.